HS
AUTL

HighVista Strategies’s Autolus Therapeutics AUTL Stock Holding History

HighVista Strategies’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-533,024
Closed -$1.25M – 150
2024
Q4 		$1.25M Hold
533,024
– – 0.47% 97
2024
Q3 		$1.93M Buy
533,024
+14,204
+3% +$56.6K 0.67% 47
2024
Q2 		$1.81M Buy
518,820
+257,496
+99% +$1.11M 0.66% 46
2024
Q1 		$1.67M Buy
+261,324
New +$1.63M 0.59% 59

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighVista Strategies's AUTL Position: Q1 2025 in Review

HighVista Strategies sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 533,024 shares — an estimated $1.25M sold.

HighVista Strategies first reported a position in AUTL in Q1 2024 and held it in 4 quarters. The position peaked at $1.93M in Q3 2024. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • HighVista Strategies reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HighVista Strategies sold 533,024 Autolus Therapeutics shares in Q1 2025, an estimated $1.25M.
  • HighVista Strategies first reported a position in Autolus Therapeutics in Q1 2024 and held it in 4 quarters.
  • HighVista Strategies's Autolus Therapeutics position peaked at $1.93M in Q3 2024.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on HighVista Strategies's 13F filing for Q1 2025, filed 15 May 2025.